LENZ Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
LENZ Therapeutics, Inc. carries a market capitalization of 186.87M, placing it among publicly traded companies globally. Its enterprise value stands at -41.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 186.87M |
| Enterprise Value | -41.46M |
Share Statistics
LENZ Therapeutics, Inc. currently has 31.35M shares outstanding.
| Shares Outstanding | 31.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 8.09, and the price-to-book ratio stands at 0.81.
| PE Ratio | N/A |
| PS Ratio | 8.09 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | -1.53 |
| P/OCF Ratio | -1.53 |
Enterprise Valuation
| EV / Sales | 76.99 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
LENZ Therapeutics, Inc. maintains a current ratio of 13.55, meaning it holds 13.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.55 |
| Quick Ratio | 12.81 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -59.21 |
| Return on Assets (ROA) | -55.52 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.66 |
Taxes
| Income Tax | 5,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
LENZ Therapeutics, Inc.'s stock has declined approximately -85.80276% over the past 52 weeks. The 50-day moving average sits at 5.27, while the 200-day moving average is 11.61.
| Beta (5Y) | N/A |
| 52-Week Price Change | -85.80276% |
| 50-Day Moving Average | 5.27 |
| 200-Day Moving Average | 11.61 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, LENZ Therapeutics, Inc. generated 21.48M in revenue and converted that into -126.00M in net income, yielding earnings per share of -3.08. EBITDA reached -135.20M, while operating income came in at -135.66M.
| Revenue | 21.48M |
| Gross Profit | 825,000.00 |
| Operating Income | -135.66M |
| Pretax Income | -126.00M |
| Net Income | -126.00M |
| EBITDA | -135.20M |
| EBIT | -135.66M |
| Earnings Per Share (EPS) | -3.08 |
Balance Sheet
LENZ Therapeutics, Inc. holds 220.00M in cash and equivalents against 447,000.00 in total debt, resulting in a net debt position of -24.21M. Total book value stands at 219.26M, with working capital of 216.07M providing operational flexibility.
| Cash & Cash Equivalents | 220.00M |
| Total Debt | 447,000.00 |
| Net Debt | -24.21M |
| Equity (Book Value) | 219.26M |
| Book Value Per Share | 6.99 |
| Working Capital | 216.07M |
Cash Flow
LENZ Therapeutics, Inc. produced -113.91M in operating cash flow over the past twelve months. After subtracting -511,000.00 in capital expenditures, free cash flow totaled -114.42M - equivalent to -3.74 per share.
| Operating Cash Flow | -113.91M |
| Capital Expenditures | -511,000.00 |
| Free Cash Flow | -114.42M |
| FCF Per Share | -3.74 |
Margins
LENZ Therapeutics, Inc. operates with a gross margin of 93.69, reflecting its pricing power and cost economics. The operating margin of -631.70 and net profit margin of -586.74 provide insight into operational efficiency.
| Gross Margin | 93.69 |
| Operating Margin | -631.70 |
| Pretax Margin | -586.71 |
| Profit Margin | -586.74 |
| EBITDA Margin | -629.59 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -69.41 |
| FCF Yield | -65.28 |
Stock Splits
LENZ Therapeutics, Inc.'s most recent stock split took place on March 22, 2024 with a 7:1 split ratio.
| Last Split Date | 3/22/2024 |
| Split Ratio | 7:1 |